Key result
Dedicated AR TAVR devices improve survival and reduce complications compared to early-generation off-label valves.
Why the study?
Early-generation TAVR devices for aortic regurgitation faced significant challenges including high mortality, residual paravalvular leaks, and valve embolisation, motivating evaluations of newer and dedicated devices.
Does transcatheter aortic valve replacement improve outcomes in high-risk or elderly patients with severe native aortic regurgitation?
Does transcatheter aortic valve replacement improve outcomes in high-risk or elderly patients with severe native aortic regurgitation?
Advancements in TAVR technology and the introduction of dedicated devices have made transcatheter treatment a viable, safer, and more effective option for high-risk patients with pure native aortic regurgitation.
Answers are grounded in this paper and cite their sources.
Supports dedicated TAVR platforms in high-risk AR; leaves open randomized confirmation before practice change.
Transcatheter aortic valve replacement (TAVR) has developed into a viable treatment for aortic regurgitation (AR), particularly in high-risk or elderly patients unable to undergo surgery. Early generation devices encountered significant challenges, including high mortality rates, residual paravalvular leaks, and complications such as valve embolisation. However, advancements in TAVR technology, including self-expanding and balloon-expandable devices, have improved procedural outcomes. Dedicated devices, such as the Trilogy system (JenaValve) and J-Valve (Edwards Lifesciences), specifically designed for AR, have demonstrated superior performance with reduced complications and better patient survival. Other devices, such as Cusper (Cuspa) and the Zeta/Alpha systems (Laguna Tech), show potential for treating complex AR cases, including those with non-calcified valves or active endocarditis. These innovations offer hope for patients with severe AR, highlighting the need for tailored approaches based on individual anatomical and pathological variations.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a review in Aortic Regurgitation. Transcatheter Aortic Valve Replacement (TAVR) vs. Surgical aortic valve replacement or off-label TAVR devices was evaluated. Dedicated transcatheter aortic valve replacement devices designed specifically for aortic regurgitation demonstrate superior performance and better patient survival with fewer complications compared to early-generation off-label devices.
Synapse has enriched 10 related papers. Consider them for comparative context: